2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.

Compass Pathways reported "successful" but underwhelming results for its Phase IIb clinical trial using psilocybin to treat Treatment Resistant Depression. We identify the winners and losers from this news.